Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats

被引:24
作者
Bradley, Daniel P.
Tessier, Jean J.
Ashton, Susan E.
Waterton, John C.
Wilson, Zena
Worthington, Philip L.
Ryan, Anderson J.
机构
[1] AstraZeneca, Discovery Enabling Capabil & Sci, Macclesfield SK10 4TG, Cheshire, England
[2] AstraZeneca, Canc & Infect Res Area, Macclesfield SK10 4TG, Cheshire, England
来源
NEOPLASIA | 2007年 / 9卷 / 05期
关键词
ZD6126; vascular-damaging agent; magnetic resonance imaging; necrosis; xenograft;
D O I
10.1593/neo.07145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Magnetic resonance imaging ( MRI) can measure the effects of therapies targeting the tumor vasculature and has demonstrated that vascular- damaging agents ( VDA) induce acute vascular shutdown in tumors in human and animal models. However, at subtherapeutic doses, blood flow may recover before the induction of significant levels of necrosis. We present the relationship between changes in MRI biomarkers and tumor necrosis. Multiple MRI measurements were taken at 4.7 T in athymic rats ( n = 24) bearing 1.94 +/- 0.2 - cm(3) subcutaneous Hras5 tumors ( ATCC 41000) before and 24 hours after clinically relevant doses of the VDA, ZD6126 ( 0 - 10 mg/ kg, i. v.). We measured effective transverse relaxation rate ( R-2*), initial area under the gadolinium concentration - time curve ( IAUGC(60/150)), equivalent enhancing fractions ( EHF60/150), time constant (K-trans), proportion of hypoperfused voxels as estimated from fit failures in K trans analysis, and signal intensity (SI) in T-2-weighted MRI ( T2W). ZD6126 treatment induced > 90% dose- dependent tumor necrosis at 10 mg/ kg; correspondingly, SI changes were evident from T2W MRI. Although R-2* did not correlate, other MRI biomarkers significantly correlated with necrosis at doses of >= 5 mg/ kg ZD6126. These data on Hras5 tumors suggest that the quantification of hypoperfused voxels might provide a useful biomarker of tumor necrosis.
引用
收藏
页码:382 / 391
页数:10
相关论文
共 50 条
  • [1] Determination of the maturity and functionality of tumor vasculature by MRI: Correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors
    Baudelet, Christine
    Cron, Gregory O.
    Gallez, Bernard
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2006, 56 (05) : 1041 - 1049
  • [2] Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status
    Beauregard, DA
    Thelwall, PE
    Chaplin, DJ
    Hill, SA
    Adams, GE
    Brindle, KM
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (11) : 1761 - 1767
  • [3] Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS
    Beauregard, DA
    Pedley, RB
    Hill, SA
    Brindle, KM
    [J]. NMR IN BIOMEDICINE, 2002, 15 (02) : 99 - 105
  • [4] Beauregard DA, 2001, CANCER RES, V61, P6811
  • [5] Blakey DC, 2002, CLIN CANCER RES, V8, P1974
  • [6] ZD6126: A novel small molecule vascular targeting agent
    Blakey, DC
    Ashton, SE
    Westwood, FR
    Walker, M
    Ryan, AJ
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (05): : 1497 - 1502
  • [7] IMMUNOHISTOCHEMICAL DETECTION OF A HYPOXIA MARKER IN SPONTANEOUS CANINE TUMORS
    CLINE, JM
    THRALL, DE
    PAGE, RL
    FRANKO, AJ
    RALEIGH, JA
    [J]. BRITISH JOURNAL OF CANCER, 1990, 62 (06) : 925 - 931
  • [8] Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice
    D'Souza, R. A.
    Partridge, E. A.
    Roberts, D. W.
    Ashton, S.
    Ryan, A.
    Patterson, A. B.
    Wilson, Z.
    Thurrell, C. C.
    [J]. XENOBIOTICA, 2007, 37 (03) : 328 - 340
  • [9] Davis PD, 2002, CANCER RES, V62, P7247
  • [10] DRUPLINK HE, 2006, CURR PHARM DESIGN, V12, P2661